Seyed Nooreddin Faraji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seyed Nooreddin Faraji has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Gholami
Biotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications Zahra Mosalanejad
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications- Emad Behboudi
Department of Basic Medical Sciences Khoy University of Medical Sciences Khoy Iran
2 shared publications - Foroogh Nejatollahi
Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications Maryam Asadi
School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications- Ali Ghaffarian-Bahraman
Occupational Environment Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
1 shared publication
Latest Publications
- 19 September 2026
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 32 (6) , 87
Macrocyclic Theta-Defensins as Dual-Action Microbicides and Pleiotropic Immunomodulators in Infectious and Inflammatory Diseases
- 19 September 2026
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 32 (6) , 87
Macrocyclic Theta-Defensins as Dual-Action Microbicides and Pleiotropic Immunomodulators in Infectious and Inflammatory Diseases
- 11 May 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (7) , 1-26
Computational Design and Biopharmaceutical Evaluation of a Chimeric Nanoparticle Vaccine for Targeted Delivery against BK Polyomavirus
Purpose To address the unmet need for a prophylactic therapy against BK polyomavirus (BKPV) in transplant recipients, this study employed a mechanism-based computational approach to design a multi-epitope chimeric nanoparticle (CNP) vaccine, predicting its biopharmaceutical and immunological profile. Methods A comprehensive computational biopharmaceutics pipeline was implemented. Conserved and immunodominant B-cell, helper T-lymphocyte (HTL), and cytotoxic T-lymphocyte (CTL) epitopes from all major BKPV proteins were identified using immunoinformatic tools. Epitopes were rigorously validated for antigenicity, safety, global population coverage, and cross-reactivity potential against JC polyomavirus. A multi-epitope construct, fused with immune-potentiating peptides, was designed and displayed on an Encapsulin nanocage via the SpyTag/SpyCatcher system to create a targeted delivery platform. Results Molecular docking and dynamics simulations demonstrated stable, high-affinity binding of the vaccine construct and the CNP with Toll-like receptors 2 and 4, predicting effective innate immune recognition. In silico immune simulation forecasted robust and durable humoral and cellular immune responses upon administration. Conclusions This integrated computational study provides a mechanistic rationale for a novel CNP vaccine candidate against BKPV. The predicted stability, immunogenicity, and targeted delivery potential establish a strong foundation for subsequent in vitro and in vivo development, aligning with the translation of computational design into biopharmaceutical products. Graphical Abstract The roadmap of chimeric nanoparticle BKPV vaccine designing. This picture originally created by BioRender and PowerPoint elements tools. The alternative text for this image may have been generated using AI.
- 11 May 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (7) , 1-26
Computational Design and Biopharmaceutical Evaluation of a Chimeric Nanoparticle Vaccine for Targeted Delivery against BK Polyomavirus
Purpose To address the unmet need for a prophylactic therapy against BK polyomavirus (BKPV) in transplant recipients, this study employed a mechanism-based computational approach to design a multi-epitope chimeric nanoparticle (CNP) vaccine, predicting its biopharmaceutical and immunological profile. Methods A comprehensive computational biopharmaceutics pipeline was implemented. Conserved and immunodominant B-cell, helper T-lymphocyte (HTL), and cytotoxic T-lymphocyte (CTL) epitopes from all major BKPV proteins were identified using immunoinformatic tools. Epitopes were rigorously validated for antigenicity, safety, global population coverage, and cross-reactivity potential against JC polyomavirus. A multi-epitope construct, fused with immune-potentiating peptides, was designed and displayed on an Encapsulin nanocage via the SpyTag/SpyCatcher system to create a targeted delivery platform. Results Molecular docking and dynamics simulations demonstrated stable, high-affinity binding of the vaccine construct and the CNP with Toll-like receptors 2 and 4, predicting effective innate immune recognition. In silico immune simulation forecasted robust and durable humoral and cellular immune responses upon administration. Conclusions This integrated computational study provides a mechanistic rationale for a novel CNP vaccine candidate against BKPV. The predicted stability, immunogenicity, and targeted delivery potential establish a strong foundation for subsequent in vitro and in vivo development, aligning with the translation of computational design into biopharmaceutical products. Graphical Abstract The roadmap of chimeric nanoparticle BKPV vaccine designing. This picture originally created by BioRender and PowerPoint elements tools. The alternative text for this image may have been generated using AI.
- Open Access
- 19 March 2025
- Published by Walter de Gruyter GmbH in Journal of Integrative Bioinformatics
- Vol. 22 (1)
Designing an optimized theta-defensin peptide for HIV therapy using in-silico approaches
The glycoproteins 41 (gp41) of human immunodeficiency virus (HIV), located on the virus’s external surface, form six-helix bundles that facilitate viral entry into the host cell. Theta defensins, cyclic peptides, inhibit the formation of these bundles by binding to the GP41 CHR region. RC101, a synthetic analog of theta-defensin molecules, exhibits activity against various HIV subtypes. Molecular docking of the CHR and RC101 was done using MDockPeP and Hawdock server. The type of bonds and the essential amino acids in binding were identified using AlphaFold3, CHIMERA, RING, and CYTOSCAPE. Mutable amino acids within the peptide were determined using the CUPSAT and Duet. Thirty-two new peptides were designed, and their interaction with the CHR of the gp41 was analyzed. The physicochemical properties, toxicity, allergenicity, and antigenicity of peptides were also investigated. Most of the designed peptides exhibited higher binding affinities to the target compared to RC101; notably, peptides 1 and 4 had the highest binding affinity and demonstrated a greater percentage of interactions with critical amino acids of CHR. Peptides A and E displayed the best physiochemical properties among designed peptides. The designed peptides may present a new generation of anti-HIV drugs, which may reduce the likelihood of drug resistance.
- 19 March 2025
- Published by Walter de Gruyter GmbH in Journal of Integrative Bioinformatics
- Vol. 22 (1)
Open AccessDesigning an optimized theta-defensin peptide for HIV therapy using in-silico approaches
The glycoproteins 41 (gp41) of human immunodeficiency virus (HIV), located on the virus’s external surface, form six-helix bundles that facilitate viral entry into the host cell. Theta defensins, cyclic peptides, inhibit the formation of these bundles by binding to the GP41 CHR region. RC101, a synthetic analog of theta-defensin molecules, exhibits activity against various HIV subtypes. Molecular docking of the CHR and RC101 was done using MDockPeP and Hawdock server. The type of bonds and the essential amino acids in binding were identified using AlphaFold3, CHIMERA, RING, and CYTOSCAPE. Mutable amino acids within the peptide were determined using the CUPSAT and Duet. Thirty-two new peptides were designed, and their interaction with the CHR of the gp41 was analyzed. The physicochemical properties, toxicity, allergenicity, and antigenicity of peptides were also investigated. Most of the designed peptides exhibited higher binding affinities to the target compared to RC101; notably, peptides 1 and 4 had the highest binding affinity and demonstrated a greater percentage of interactions with critical amino acids of CHR. Peptides A and E displayed the best physiochemical properties among designed peptides. The designed peptides may present a new generation of anti-HIV drugs, which may reduce the likelihood of drug resistance.
- Open Access
- 20 November 2024
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 08 (04) , 1-25
Epstein-Barr Virus and Helicobacter pylori as Two Main Risk Factors in Gastric Cancer
Microbial and viral pathogens have emerged as key contributors to cancer development. Research conducted in the last twenty years has significantly enhanced our comprehension of the cancer-causing capabilities of infectious agents. An illustrative instance is gastric cancer (GC), which is closely associated with Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV) infections, with approximately 90% of non-cardia GC cases attributed to H. pylori infection and around 10% linked to EBV. Despite significant research efforts, GC remains a severe clinical challenge, ranking as the fifth most commonly diagnosed cancer worldwide. In 2020, an estimated 768,793 people died from GC in the world. The pathogenicity island (PAI), cagA protein, VacA, and other virulence factors in H. pylori and several latency factors such as EBNA-1, LMP-1, and LMP2A in Epstein-Barr virus, as well as pattern of gene methylation and EBV and H. pylori co-infection are shown as the leading causes of pathogen-related GC. The unique molecular and clinical characteristics associated with EBV and H. pylori in GC highlight the importance of further understanding their respective roles in GC development and progression. This knowledge may inform future preventive and therapeutic strategies targeting these infectious agents in the context of GC. This review aims to elucidate the mechanisms underpinning GC's EBV and H. pylori-induced carcinogenesis.
- 20 November 2024
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 08 (04) , 1-25
Open AccessEpstein-Barr Virus and Helicobacter pylori as Two Main Risk Factors in Gastric Cancer
Microbial and viral pathogens have emerged as key contributors to cancer development. Research conducted in the last twenty years has significantly enhanced our comprehension of the cancer-causing capabilities of infectious agents. An illustrative instance is gastric cancer (GC), which is closely associated with Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV) infections, with approximately 90% of non-cardia GC cases attributed to H. pylori infection and around 10% linked to EBV. Despite significant research efforts, GC remains a severe clinical challenge, ranking as the fifth most commonly diagnosed cancer worldwide. In 2020, an estimated 768,793 people died from GC in the world. The pathogenicity island (PAI), cagA protein, VacA, and other virulence factors in H. pylori and several latency factors such as EBNA-1, LMP-1, and LMP2A in Epstein-Barr virus, as well as pattern of gene methylation and EBV and H. pylori co-infection are shown as the leading causes of pathogen-related GC. The unique molecular and clinical characteristics associated with EBV and H. pylori in GC highlight the importance of further understanding their respective roles in GC development and progression. This knowledge may inform future preventive and therapeutic strategies targeting these infectious agents in the context of GC. This review aims to elucidate the mechanisms underpinning GC's EBV and H. pylori-induced carcinogenesis.
- 29 August 2024
- Published by Elsevier in Human Immunology
- Vol. 85 (5) , 111090
Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review
- 29 August 2024
- Published by Elsevier in Human Immunology
- Vol. 85 (5) , 111090
Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review
- Open Access
- 1 January 2024
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2024 (1) , 6675459
The Effect of Nanocurcumin Supplementation on Inflammatory and Biochemical Indicators in Hospitalized Patients With COVID‐19: A Randomized Controlled Clinical Trial
Background: The prior studies showed that nanocurcumin (NC) has potential anti‐viral properties against a wide range of viral infections, making it a promising candidate for treating COVID‐19. This study aimed to investigate the effect of NC supplementation on the acute phase proteins, including interleukin‐6 (IL‐6), C‐reactive protein (CRP), albumin (ALB) and Erythrocyte Sedimentation Rate (ESR), and biochemical markers including lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine transaminase (ALT) and complete blood cells (CBC) in the hospitalized patients with Coronavirus disease 2019 (COVID‐19).Methods and Materials: In a double‐blind placebo‐controlled clinical trial conducted at Ali‐Asghar Hospital of Shiraz University of Medical Sciences, 76 COVID‐19 patients with mild to moderate disease severity were randomly assigned to two groups. All patients received the national treatment guideline for COVID‐19. The intervention group was administered 160 mg/day of NC for a period of 2 weeks. Blood samples were obtained at the start and the end of the research, and nutritional consumption was determined using a 24 h dietary recall.Results: The mean age of participants in the NC and placebo groups was 54.69 ± 13.44 and 53.94 ± 11.62 years, respectively. In the NC group, compared with placebo group, the levels of IL‐6 (p = 0.017) and LDH (p = 0.004) was significantly reduced. There was no significant difference in the mean changes of AST (p = 0.197), ALT (p = 0.086), ALB (p = 0.560), CRP (p = 0.197), ESR (p = 0.298), hemoglobin (Hb) (p = 0.372), white blood cells (WBC) (p = 0.995), neutrophils (p = 0.264), and lymphocyte (p = 0.418) between two groups.Conclusion: According to the research results, it seems that adding NC supplementation to the treatment plan for COVID‐19 patients who are hospitalized and have mild to moderate illness severity might possibly reduce inflammation.Trial Registration: ClinicalTrials.gov identifier: IRCT20211126053183N1.
- 1 January 2024
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2024 (1) , 6675459
Open AccessThe Effect of Nanocurcumin Supplementation on Inflammatory and Biochemical Indicators in Hospitalized Patients With COVID‐19: A Randomized Controlled Clinical Trial
Background: The prior studies showed that nanocurcumin (NC) has potential anti‐viral properties against a wide range of viral infections, making it a promising candidate for treating COVID‐19. This study aimed to investigate the effect of NC supplementation on the acute phase proteins, including interleukin‐6 (IL‐6), C‐reactive protein (CRP), albumin (ALB) and Erythrocyte Sedimentation Rate (ESR), and biochemical markers including lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine transaminase (ALT) and complete blood cells (CBC) in the hospitalized patients with Coronavirus disease 2019 (COVID‐19).Methods and Materials: In a double‐blind placebo‐controlled clinical trial conducted at Ali‐Asghar Hospital of Shiraz University of Medical Sciences, 76 COVID‐19 patients with mild to moderate disease severity were randomly assigned to two groups. All patients received the national treatment guideline for COVID‐19. The intervention group was administered 160 mg/day of NC for a period of 2 weeks. Blood samples were obtained at the start and the end of the research, and nutritional consumption was determined using a 24 h dietary recall.Results: The mean age of participants in the NC and placebo groups was 54.69 ± 13.44 and 53.94 ± 11.62 years, respectively. In the NC group, compared with placebo group, the levels of IL‐6 (p = 0.017) and LDH (p = 0.004) was significantly reduced. There was no significant difference in the mean changes of AST (p = 0.197), ALT (p = 0.086), ALB (p = 0.560), CRP (p = 0.197), ESR (p = 0.298), hemoglobin (Hb) (p = 0.372), white blood cells (WBC) (p = 0.995), neutrophils (p = 0.264), and lymphocyte (p = 0.418) between two groups.Conclusion: According to the research results, it seems that adding NC supplementation to the treatment plan for COVID‐19 patients who are hospitalized and have mild to moderate illness severity might possibly reduce inflammation.Trial Registration: ClinicalTrials.gov identifier: IRCT20211126053183N1.
- 16 May 2022
- Published by Springer Nature in BioMetals
- Vol. 35 (4) , 711-728
Contamination of breast milk with lead, mercury, arsenic, and cadmium in Iran: a systematic review and meta-analysis
Breast milk is a complete food for the development of the newborn, but it can also be an important route for environmental pollutants transmission to the infants. This study was aimed to evaluate the status of heavy metals including lead (Pb), mercury (Hg), cadmium (Cd) and arsenic (As) in the breast milk of Iranian mothers. The international databases including Scopus, PubMed, Web of Science and the Persian electronic databases including Scientific Information Database, IranMedex and Magiran were examined to find relevant articles published until July 2021. A total of 23 studies examined the levels of toxic metals in Iranian breast milk samples. According to the findings, the pooled average concentrations (µg/L) of Pb, Cd, Hg and As were 25.61, 2.40, 1.29 and 1.16, respectively. The concentration of Hg and Pb in colostrum milk was more than twice of mature milk. The Hg mean concentration in the breast milk of mothers with at least one amalgam-filled tooth was approximately three times that of mothers without amalgam-filled teeth. Risk assessment analysis indicated that the intake of Pb and Hg by infants through breastfeeding can be considered a health concern in Iran. It seems necessary to reduce the Pb exposure of pregnant and lactating women in Iran. However, more extensive studies are needed to clarify the toxic metals’ exposure status of infants through breast milk in other parts of the country.
- 16 May 2022
- Published by Springer Nature in BioMetals
- Vol. 35 (4) , 711-728
Contamination of breast milk with lead, mercury, arsenic, and cadmium in Iran: a systematic review and meta-analysis
Breast milk is a complete food for the development of the newborn, but it can also be an important route for environmental pollutants transmission to the infants. This study was aimed to evaluate the status of heavy metals including lead (Pb), mercury (Hg), cadmium (Cd) and arsenic (As) in the breast milk of Iranian mothers. The international databases including Scopus, PubMed, Web of Science and the Persian electronic databases including Scientific Information Database, IranMedex and Magiran were examined to find relevant articles published until July 2021. A total of 23 studies examined the levels of toxic metals in Iranian breast milk samples. According to the findings, the pooled average concentrations (µg/L) of Pb, Cd, Hg and As were 25.61, 2.40, 1.29 and 1.16, respectively. The concentration of Hg and Pb in colostrum milk was more than twice of mature milk. The Hg mean concentration in the breast milk of mothers with at least one amalgam-filled tooth was approximately three times that of mothers without amalgam-filled teeth. Risk assessment analysis indicated that the intake of Pb and Hg by infants through breastfeeding can be considered a health concern in Iran. It seems necessary to reduce the Pb exposure of pregnant and lactating women in Iran. However, more extensive studies are needed to clarify the toxic metals’ exposure status of infants through breast milk in other parts of the country.